Skip to main content
S&P 5007,619.98-0.48%DOW52,421.20-0.29%NASDAQ26,186.41-0.56%BTC$77,995.00+1.59%ETH$2,515.85+1.31%GOLD$4,333.30-0.43%OIL$102.74+1.33%
Smart Investors Daily
IC

NASDAQ · ICUCW

SeaStar Medical Holding Corporation

Healthcare · Biotechnology

$0.02

Down-$0.00 (-6.29%)

Updated Sep 15, 2026, 9:23 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
475.82K
P/E ratio
-0.66
Dividend yield
0.00%
52-week range
$0.01 – $0.08
Volume
10.71K
Avg. volume
69.42K

Price performance

ICUCW price history

1M range · 17 trading sessions · Daily adjusted prices

ICUCW closed at $0.02 after 17 trading sessions, down 29.02% for the selected period.

Last close
$0.02
Period change
-29.02%
Period low
$0.01
Period high
$0.02
Daily close
View OHLC price history
ICUCW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$0.0159$0.0159$0.0159$0.015910.71K
Sep 10, 2026$0.0151$0.016$0.014$0.015816.13K
Sep 9, 2026$0.0156$0.0163$0.0141$0.0141890
Sep 8, 2026$0.0158$0.0158$0.0158$0.01581.02K
Sep 4, 2026$0.0163$0.0163$0.0162$0.016211.95K
Sep 3, 2026$0.0151$0.0163$0.0137$0.016336.98K
Sep 2, 2026$0.0152$0.0166$0.0151$0.016614.46K
Sep 1, 2026$0.0151$0.0169$0.0151$0.01699.02K
Aug 31, 2026$0.0152$0.0169$0.0152$0.01692.44K
Aug 28, 2026$0.015$0.0185$0.0136$0.017684.32K
Aug 27, 2026$0.0153$0.0174$0.0153$0.01736.89K
Aug 26, 2026$0.0168$0.0194$0.0167$0.016712.26K
Aug 25, 2026$0.017$0.0198$0.0168$0.019725.14K
Aug 24, 2026$0.0174$0.0191$0.0173$0.01918.69K
Aug 20, 2026$0.0201$0.0201$0.0175$0.019620.01K
Aug 19, 2026$0.0247$0.0247$0.0196$0.02121.98K
Aug 17, 2026$0.0197$0.0225$0.0197$0.0224320

Latest ICUCW news

The latest Smart Investors Daily articles mentioning ICUCW.

Stock researchCompany · Overview

ICUCW research

Overview

Company profile and research snapshot.

Company profile

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City. The SeaStar Medical presentatio

Yahoo · Aug 12, 2026

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

Added 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with AKI Obtained ICD-10-PCS codes to enable standardized inpatient hospital billing for its selective cytopheretic device (SCD) therapy, including QUELIMMUNE Webcast today at 4:30 pm Eastern Time DENVER, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Hol

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By